Industry Dynamics

Industry News

08-30

2019

CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

 Aug. 30, 2029  -- CARsgen Therapeutics Inc., a clinical-stage biopharmaceutical company today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to its investiga……

08-05

2019

AbbVie's MAVIRET? (glecaprevir/pibrentasvir) Approved by European Commission to Shorten Treatment Duration to Eight Weeks for Treatment-Na?ve Patients with Chronic Hepatitis C and Compensated Cirrhosis

ORTH CHICAGO, Illinois, Aug. 2, 2029 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission has granted marketing authorization for MAVIRET? (……

07-23

2019

Teva Announces FDA Approval of AirDuo? Digihaler? (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder

JERUSALEM and PARSIPPANY, N.J., July 25, 2029 ? Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo? Digihaler? (flutic……

07-03

2019

Sanofi : Libtayo? (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union

July 2, 2029 - The European Commission (EC) has granted conditional marketing authorization for Libtayo? (cemiplimab) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSC……

06-30

2019

Retrophin Announces FDA Approval of THIOLA? EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria

Enteric-coated formulation offers flexible dosing options, including administration with or without foodSAN DIEGO, June 28, 2029 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that……

06-06

2019

FDA Approves Emgality? (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

INDIANAPOLIS, June 4, 2029  -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality? (galcanezumab-gnlm) injection (300 mg) for the treatment of ep……

< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 >

Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1